Mallinckrodt Pharmaceuticals
387 articles about Mallinckrodt Pharmaceuticals
-
All Primary and Secondary Outcome Targets Met in Mallinckrodt's Phase 4 Acthar® Gel (Repository Corticotropin Injection) Rheumatoid Arthritis (RA) Clinical Trial (n=259) with Data Presented at the European Congress of Rheumatology 2019 (EULAR)
6/13/2019
Study met primary outcome measure; 63 percent of patients with persistently active RA achieved low disease activity (LDA) as assessed by DAS28-ESR¹ at Week 12
-
Mallinckrodt to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference
6/11/2019
Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, will present on Tuesday, June 25, 2019, at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference at the Mandarin Oriental, 80 Columbus Circle, New York.
-
Mallinckrodt to Present at Raymond James Life Sciences and Medtech Conference
5/31/2019
Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, will present on Wednesday, June 19, 2019, at the Raymond James Life Sciences and MedTech Conference at the Lotte New York Palace, 455 Madison Ave, New York.
-
Mallinckrodt Announces Positive Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Rheumatoid Arthritis (RA) to be Presented at the European Congress of Rheumatology 2019 (EULAR)
5/29/2019
Mallinckrodt plc, a global specialty biopharmaceutical company, is reporting data1 from the open-label part of the Phase 4, multicenter study assessing the efficacy and safety of Acthar® Gel in patients with persistently active rheumatoid arthritis who were previously treated with disease-modifying anti-rheumatic drugs and corticosteroids.
-
Mallinckrodt Updates Plans for Company Separation and Spin-Off of Specialty Generics Business to Shareholders
5/28/2019
Mallinckrodt plc announced updated plans for its spin-off of a new company consisting of Mallinckrodt's Specialty Generics/Active Pharmaceutical Ingredients business to Mallinckrodt plc shareholders.
-
Mallinckrodt Files Suit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) to Protect Medicaid Patient Access to Acthar® Gel
5/21/2019
Mallinckrodt plc confirmed its subsidiary, Mallinckrodt ARD LLC, has filed suit in federal district court against the HHS and CMS.
-
Mallinckrodt Completes Enrollment of Phase 3 Terlipressin CONFIRM Trial
5/14/2019
Mallinckrodt's CONFIRM study is evaluating the efficacy and safety of terlipressin in hepatorenal syndrome type 1
-
Mallinckrodt plc Reports Strong Growth in First Quarter 2019 Results, Raises Guidance for 2019, and Continues to Make Significant Advancements in Pipeline and Data Generation
5/7/2019
Net sales up 4.7%, or 5.0% on a constant-currency basis, on $790.6 million, led by strong performance of hospital products and the Specialty Generics and Amitiza segment
-
Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients with Familial Adenomatous Polyposis
5/7/2019
Full data to be presented in detail by CPP at Digestive Disease Week (DDW) conference on May 19, 2019 at 5:19 pm Pacific Time
-
Mallinckrodt Announces Encouraging Interim Analysis Results in Phase 4 Registry of INOmax® (Nitric Oxide) Gas for Inhalation for Pulmonary Hypertension in Neonates
5/6/2019
Observational registry (at midway point) with retrospective data collection provides preliminary evaluation of premature versus term and near-term neonates with pulmonary hypertension receiving inhaled nitric oxide
-
Mallinckrodt Lupus Phase 4 Clinical Study for Acthar® Gel (Repository Corticotropin Injection) Completes Enrollment in Difficult-to-Manage Population
4/23/2019
Company continues focus on evidence expansion, potential utility of Acthar Gel in appropriate, underserved patients
-
Mallinckrodt Reports Top-Line Results from Proof-of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung Transplants
4/18/2019
Study showed oxygenation improvement and increased out-of-body perfusion duration
-
Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress™ (EASL)
4/15/2019
Retrospective analysis showed applying latest International Club of Ascites (ICA) diagnostic criteria would be estimated to result in earlier time to treatment at a lower SCr level and potentially improved outcomes
-
Mallinckrodt Completes Full Enrollment of its Phase 3 Clinical Trial for StrataGraft® Regenerative Skin Tissue
4/12/2019
Pivotal Phase 3 study is evaluating efficacy and safety of investigational regenerative skin tissue in adults with deep partial-thickness burns
-
Mallinckrodt and Washington University St. Louis Select First Collaborative Research Endeavor
4/11/2019
Discovery program aimed at identifying potential new drugs targeting chronic itch, a serious condition spanning multiple disorders
-
Data Published on Acthar® Gel (repository corticotropin injection) Disease Status and Utilization Patterns in Uveitis Patients in Journal of Ocular Pharmacology and Therapeutics
4/9/2019
Retrospective chart review also reports on use of concomitant uveitis medication during and after treatment with Acthar Gel
-
Mallinckrodt Achieves Top Score in 2019 Corporate Equality Index for Third Year in a Row, Recognized as a Best Place to Work for LGBTQ Equality
3/28/2019
Company earns 100 percent on Human Rights Campaign Foundation's 17th annual scorecard on LGBTQ Workplace Equality
-
Mallinckrodt plc To Report Earnings Results For First Quarter 2019
3/27/2019
Mallinckrodt plc, a leading global specialty pharmaceutical company, announced that it will report first quarter 2019 earnings results for the period ending March 29, 2019, on Tuesday, May 7, 2019.
-
St. Louis, Missouri is one of the fastest-growing and top-ranked emerging life sciences markets in the U.S., ranking sixth in a recent CBRE Research report.
-
Bryan Reasons Joins Mallinckrodt as the Company's Chief Financial Officer (CFO)
3/18/2019
Brings substantial CFO, finance expertise and pharmaceutical industry experience